Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Atherogenic Index of Plasma At-admission of COVID-19 Patients Can Predict Upcoming Cardiac Morbidity and Mortality in Non-Cardiac Patients

NCT05226377 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT05226377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05226377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Atherogenic Index of Plasma At-admission of COVID-19 Patients Can Predict Upcoming Cardiac Morbidity and Mortality in Non-Cardiac Patients
Lead sponsor
Tanta University
Phase
Observational
Overall status
Completed
Start date
March 7, 2021
Completion date
September 1, 2021
Enrollment
302 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19